A 90Y-labelled anti-ROBO1 monoclonal antibody exhibits antitumour activity against hepatocellular carcinoma xenografts during ROBO1-targeted radioimmunotherapy by Kentaro Fujiwara et al.
Fujiwara et al. EJNMMI Research 2014, 4:29
http://www.ejnmmires.com/content/4/1/29ORIGINAL RESEARCH Open AccessA 90Y-labelled anti-ROBO1 monoclonal antibody
exhibits antitumour activity against hepatocellular
carcinoma xenografts during ROBO1-targeted
radioimmunotherapy
Kentaro Fujiwara1, Keitaro Koyama1, Kosuke Suga2, Masako Ikemura3, Yasutaka Saito4, Akihiro Hino4,
Hiroko Iwanari5, Osamu Kusano-Arai5,6, Kenichi Mitsui5, Hiroyuki Kasahara4, Masashi Fukayama3, Tatsuhiko Kodama7,
Takao Hamakubo5 and Toshimitsu Momose1*Abstract
Background: ROBO1 is a membrane protein that functions in axon guidance. ROBO1 contributes to tumour
metastasis and angiogenesis and may have potential as a target protein of immunotherapy because ROBO1 is
specifically expressed at high levels in hepatocellular carcinoma. In this study, we examined biodistribution and
radioimmunotherapy (RIT) using a radioisotope-labelled anti-ROBO1 monoclonal antibody (MAb) against
hepatocellular carcinoma models.
Methods: ROBO1-positive HepG2 human hepatocellular carcinoma xenograft nude mice were used in this study.
We conjugated anti-ROBO1 MAb with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), and the
conjugates were labelled with 111In and 90Y. To study biodistribution, the 111In-DOTA-anti-ROBO1 MAb was injected
into HepG2 xenograft mice via the tail vein. To evaluate any antitumour effect, a RIT study was performed, and the
90Y-DOTA-anti-ROBO1 MAb was injected via the tail vein. Tumour volume, mouse weight, and blood cell count
were periodically measured throughout the experiments. The tumours and organs of mice were collected, and a
histopathological analysis was carried out.
Results: The tumour uptake of 111In-anti-ROBO1 MAb in HepG2 xenograft mice was 15.0% ± 0.69% injected dose
per gram at 48 h after injection.
Immunotherapy with cold-anti-ROBO1 MAb (70 μg) did not cause a significant antitumour effect. RIT with 6.7
MBq of 90Y-anti-ROBO1 MAb caused significant tumour growth suppression. Transient body weight loss and
bone-marrow suppression were observed. Histopathological analyses of tumours revealed the fatal degeneration
of tumour cells, significant reduction of the Ki-67 index, and an increase of the apoptosis index. Normal organs
showed no significant injury, but a transient reduction of hematopoietic cells was observed in the spleen and in
the sternal bone marrow.
Conclusions: These results suggest that RIT with 90Y-anti-ROBO1 MAb is a promising treatment for ROBO1-positive
hepatocellular carcinoma.
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Hepatocellular carcinoma (HCC) is a malignant tumour
derived from hepatocytes. Primary liver cancer is the
third most common cause of death from cancer worldwide,
and patients have a poor prognosis [1,2]. The primary
treatments for HCC are surgical resection, transplantation,
and chemoembolisation. Sorafenib, an oral multikinase in-
hibitor, is the standard medicine administered for advanced
HCC. However, Sorafenib treatment does not result in re-
mission or improved survival [1]. Systemic chemotherapy
has no survival benefit [1,3]. Therefore, the development of
more effective therapeutic drugs for HCC is required.
Radioimmunotherapy (RIT) is a type of radiotherapy
using a radio-labelled monoclonal antibody (MAb) that
targets a tumour-specific antigen [4-6]. RIT can attack
targeted antigen-positive tumour cells and also antigen-
negative tumour cells by the cross-fire effect [6,7].
Although Zevalin and Bexxar have been successfully used
to treat relapsed or refractory non-Hodgkin's lymphomas,
the success of RIT as treatment for solid tumours has been
limited, due to the radioresistance of solid tumours and an
inability to deliver a sufficient dose to bulky tumours with-
out bone-marrow toxicity [4,6,8]. However, RIT has the
potential to be therapeutically efficacious for metastasis as
well as primary lesion [6].
The human homologue of the Drosophila roundabout
gene, ROBO1, encodes an axon guidance receptor that is
classified in a novel subfamily of the immunoglobulin (Ig)
superfamily and is highly conserved in species ranging
from fruit flies to mammals [9,10]. Previous reports indi-
cate that ROBO1 contributes to tumour metastasis and
angiogenesis [11-13]. In fact, ROBO1 is up-regulated in
85% of HCC cases [14]. Therefore, ROBO1 has potential
as a target protein of RIT for HCC.
In this study, the pharmacokinetics of an 111In (half-life
2.8 days)-labelled anti-ROBO1 MAb (111In-anti-ROBO1)
was investigated in vivo by a biodistribution study. Then,
RIT using a 90Y (half-life 2.7 days)-labelled anti-ROBO1
MAb (90Y-anti-ROBO1) was carried out to evaluate anti-
tumour activity and the effect of radiation exposure on
normal organs, with respect to pathology. In this report,
we demonstrate antitumour effects of 90Y-anti-ROBO1 on
xenograft tumours in nude mice.
Methods
Cell culture and animal models
A HepG2 human HCC cell line was purchased from
Health Science Research Resources Bank (Osaka, Japan).
Male BALB/c nude mice (4 to 5 weeks of age) were pur-
chased from CLEA Japan Inc. (Tokyo, Japan). HepG2 cells
were grown in DMEM and cultured in a medium supple-
mented with 10% (v/v) foetal bovine serum at 37°C in a
humidified atmosphere with 5% CO2. For the HepG2
tumour-bearing animal models, the HepG2 cells (2 × 106,200 μL) were inoculated subcutaneously into the right
flanks of male BALB/c nude mice. At 5 weeks after inocu-
lation, the mice were subjected to the studies. All animal
studies were approved by the Animal Care Committee of
The University of Tokyo.
Sf9 cells were cultured in Grace's supplemented media
(Invitrogen) containing 10% foetal calf serum, as de-
scribed [15].
Antibodies
A MAb against human ROBO1 was generated as previ-
ously described [14,15]. Briefly, human ROBO1 cDNA
was polymerase chain reaction (PCR)-amplified from
Alexander cells and inserted into the pBlueBac 4.5-TOPO
vector. The recombinant baculovirus expressing ROBO1
was immunized directly into gp64 transgenic mice. A posi-
tive hybridoma clone, B5209B, was selected by the reactiv-
ity to the ROBO1 stable cell line, by flow cytometry. An
anti-hemagglutinin (HA) antibody was purchased from
Sigma (St. Louis, MO, USA). MAb B5209B was purified
by ammonium sulphate precipitation from the ascitic
fluid of nude mice, to which the hybridoma cells were
implanted intraperitoneally. To raise a MAb, which
recognizes cell surface ROBO1, gp64 transgenic mice were
immunized subcutaneously with 1 mg of ROBO1-expressing
budded baculovirus with pertussis toxin adjuvant, as
previously described [15].
Evaluation of ROBO1-binding affinity of the anti-ROBO1
antibody
To evaluate binding affinities of the MAb against ROBO1,
we prepared a stable ROBO1-expressing cell line and a
soluble form of the ROBO1 (sROBO) protein.
The sROBO protein was affinity-purified from the cul-
ture supernatant of Sf9 cells infected with recombinant
baculoviruses, which harboured a gene fragment encoding
the extracellular domain of the human ROBO1 (1-861 aa)
protein with V5 and 6 ×His tags at its C-terminus.
A CHO cell line stably expressing ROBO1 fused with
an HA tag (ROBO1-HA) was generated using the Flp-In
System (Life Technologies Japan Corp., Tokyo, Japan).
ROBO1 fused to HA, encoding the tag at the C-terminal,
was inserted into the pcDNA5/FRT vector and was
co-transfected with the pOG44 vector to Flp-In-CHO
cells using Lipofectamine 2000. A highly ROBO1-HA-
expressing clone was selected from the 1 mg/mL
hygromycin-resistant cells.
Specificity and affinity of the anti-ROBO1 antibody,
B5209B, were evaluated using flow cytometry or cell
ELISA, as previously described [15,16]. For flow cytome-
try, wild type or ROBO1-HA-expressing Flp-In-CHO
cells were incubated with primary antibodies for 1 h at a
concentration of 1 μg/mL. For the anti-HA antibody,
0.02% saponin was added for permeabilisation. The cells
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albumin and 0.1 mM EDTA in PBS) and reacted with
R-Phycoerythrin conjugated anti-mouse IgG (Jackson
ImmunoResearch Laboratories, West Grove, PA, USA)
diluted to 1:200 with dilution buffer. Finally, cells were
washed twice with dilution buffer and analysed by flow
cytometry (GUAVA EasyCyte™ Plus System; Millipore,
Billerica, MA, USA).
For the cell ELISA, 105 cells/well were plated on poly-
D-lysine-coated, 96-well plates. The plates were centri-
fuged at 2,000 rpm for 1 min, and supernatants were
discarded. Then, the plates were blocked with blocking
buffer [40% Block Ace (Dainippon Sumitomo Pharma,
Osaka, Japan) in 10 mM Tris-buffered saline (TBS)] for
30 min. Cells were incubated with primary antibody of
various concentrations in blocking buffer for 1 h. After
washing twice with 0.05% Tween 20 in saline, cells were
incubated for 30 min with peroxidase-conjugated anti-
mouse IgG Fc-specific (Jackson ImmunoResearch). After
washing three times, the enzymatic reaction was visualized
with TMB Soluble Reagent (ScyTek Laboratories, Logan,
UT, USA). After the reaction was stopped with TMB
Stop Buffer (ScyTek Laboratories), the absorbance was
measured at 450 nm using a microplate reader (Biotrak II;
GE Healthcare, Piscataway, NJ, USA). The data were fitted
with a four parameter logistic curve (Figure 1c).Figure 1 Reactivity of anti-ROBO1 MAb. Specific binding of (a) anti-HA
open histogram, ROBO1-HA-expressing Flp-In-CHO cells) by flow cytometry
(filled circle, wild type CHO-cells; open circle, ROBO1-HA-expressing Flp-In-CDOTA conjugation and radiolabelling
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
(DOTA) was purchased from Macrocyclics (Dallas, TX,
USA). 111InCl3 was obtained from Nordion Inc. (Vancouver,
Canada). 90YCl3 was obtained from Eckert and Ziegler
(Braunschweig, Germany).
The anti-ROBO1 MAb in 0.1 M NaHCO3 buffer
(pH 9.0) was conjugated to DOTA at a molar ratio of 1:10
(protein to chelate). After incubation for 1 h at 37°C, the
MAb-chelate was purified on an ultra-filtration column
(ultra-4; Millipore, Billerica, MA, USA).
90YCl3 was added to the DOTA-anti-ROBO1 MAb in
0.25 M ammonium acetate buffer (pH 5.5). The mixture
was incubated for 1 h at 45°C. The 90Y-DOTA-anti-
ROBO1 MAb (90Y-anti-ROBO1) was purified on a desalt-
ing column equilibrated with PBS (NAP-5 column; GE
Healthcare, Buckinghamshire, UK).
Labelling yield and radiochemical purity were esti-
mated by instant thin layer chromatography (Pall Corp.,
MI, USA). A similar procedure was used to prepare the
111In-DOTA-anti-ROBO1 MAb (111In-anti-ROBO1).
Competitive ELISA was implemented to assess po-
tency of the anti-ROBO1 MAb, DOTA-anti-ROBO1
MAb, and 90Y- and 111In-anti-ROBO1 MAb. sROBO
was coated onto 96-well assay plates, and then plates
were blocked by Tris buffer containing 1% BSA. Theantibody and (b) anti-ROBO1 IgG (filled histogram, wild type CHO-cells;
. (c) Dose-dependent reactivity of the anti-ROBO1 IgG by cell ELISA
HO cells).
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horse radish peroxidase (HRP)-labelled anti-ROBO1
MAb (HRP-anti-ROBO1; The University of Tokyo). Ali-
quots of the mixed solution were added to each well of
the assay plate and incubated for 2 h at 37°C. The assay
plate was washed with TBS-T, and TMB solution was
added to each well and incubated for 5 min at room
temperature. Absorbance was measured at 450-nm
wavelength with a microplate reader (SpectraMax;
Molecular Devices, Sunnyvale, CA, USA). IC50 was calcu-
lated using GraphPad Prism4 software (GraphPad; San
Diego, CA, USA).
Biodistribution study
HepG2 xenograft (858.3 ± 237 mm3) mice were ran-
domly divided into six groups (n = 3 per group). Each
mouse was injected with 0.37 MBq of 111In-anti-ROBO1
(10 μg) via the tail vein. The mice were euthanised at 6,
24, 48, 72, 144, and 240 h after injection. Blood, heart,
lung, liver, kidney, spleen, stomach, intestine, muscle,
femoral bone, sternum, and tumour were collected,
weighed, and measured for radioactivity. The percentage
of injected dose per gram of tissue (% ID/g) was calcu-
lated for each organ.
RIT and immunotherapy
HepG2 xenograft mice were randomly divided into three
groups (n = 4 to 5 per group). Mice were injected via the
tail vein with a single dose of 6.7 MBq of either 90Y-anti-
ROBO1 (70 μg, n = 5 mice), cold-anti-ROBO1 MAb
(70 μg, n = 4 mice), or saline (n = 5 mice). Tumour vol-
umes for the mice in the 90Y-anti-ROBO1, cold-anti-
ROBO1, and saline groups were 674.9 ± 315, 545.0 ± 342,
and 437.6 ± 223 mm3, respectively.
The tumour size, body weight, and blood cell count
were measured twice a week until day 28 after injection.
The tumour volume was calculated using the following
formula: 0.5 × (shortest diameter)2 × (longest diameter).
Tumour growth (%) was calculated using the formula:
(tumour volume at each time point)/(tumour volume on
day0) × 100. Peripheral blood was collected from the tail
vein and then tested in an automated haematology ana-
lyser, Celltac α (MEK-6400; Nihon Kohden, Tokyo,
Japan).
Mice were euthanised when the tumour size
was >1,500 mm3 or the body weight decreased by >20%
of its original weight.
Histological analysis
Tissue specimens of HepG2 tumour, liver, kidney, intes-
tine, spleen, femoral bone, and sternum were obtained
from mice at day 0, 7, 14, and 28 after injection of 90Y-
anti-ROBO1 (n = 3 per group). All samples were fixed in
4% paraformaldehyde overnight at 4°C. They wereembedded in paraffin, and 3 to 5 μm sections were ob-
tained. The femoral bone and sternum samples were
decalcified before embedding in paraffin. Slide sections,
excluding the femoral bone and sternum, were deparaf-
finised, dehydrated, and stained with haematoxylin and
eosin (H&E). Femoral bone and sternum sections were
stained with Giemsa solution.
Ki-67 staining and terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labelling (TUNEL) were carried
out on HepG2 sections to investigate the status of tumour
cell proliferation and apoptosis, respectively.
For Ki-67 stain, antigen retrieval was performed in
10 mM citrate buffer solution (pH 6.0) in a pressure
cooker for 15 min. Endogenous peroxidase activity was
quenched using 0.3% hydrogen peroxide-methanol for
30 min, and then the specimens were blocked with 5%
normal goat serum for 1 h. Specimens were incubated
with Ki-67 MAb (1:100; DAKO, Carpinteria, CA, USA)
overnight at 4°C. Next, the specimens were treated with
a secondary antibody (simple Stain MAX-PO; Nichirei,
Tokyo, Japan) for 30 min. To visualize peroxidase activity,
0.2 mg/mL 3,3′-diaminobenzidine (Dojindo Laboratories,
Kumamoto, Japan) was used as the substrate in 0.05 M
Tris-HCl buffer (pH 7.6) containing 0.01% H2O2. Nuclear
staining was achieved with haematoxylin.
Apoptosis was detected using ApopTag Plus Peroxidase
In Situ Apoptosis Detection Kit (Chemicon International,
Inc., Billerica, MA, USA) for TUNEL, per the manufactur-
er's instructions.
Proliferative and apoptotic cells were quantified by
determining the percentage of Ki-67-positive and TUNEL-
positive cells, respectively. Two regions of interest measur-
ing 200 × 200 μm were established on each tumour per one
section. The percentage of positive-stained cells among all
the counted tumour cells was calculated.
Statistical analysis
Data are expressed as the mean ± standard deviation
(SD). Statistical analyses were carried out using JMP Pro
9.0.3 software. Means were compared using one-way
ANOVA and Student's t test. p values <0.05 were con-
sidered statistically significant.
Results
The following are the gathered results:
1. ROBO1-binding affinity of the anti-ROBO1 MAb
The ROBO1 binding activity of the selected
hybridoma clone, B5209B, was evaluated using
ROBO1-expressing CHO cells. MAb B5209B
exhibited specific binding to ROBO1-expressing
CHO cells, as compared to the positive control
anti-HA antibody (Figure 1a,b). A dose-dependent
binding study to ROBO1-expressing cells showed a
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half-maximal binding to cell surface ROBO1 was
estimated to be approximately 32.5 ng/mL from the
fitted curve in ELISA (Figure 1c).
2. DOTA conjugation and radiolabelling
Labelling yields and radiochemical purification of
90Y- and 111In-anti-ROBO1 were greater than 99%.
Competitive ELISA revealed that anti-ROBO1,
DOTA-anti-ROBO1, and 90Y- and 111In-anti-ROBO1
inhibited the binding of HRP-anti-ROBO1 to the
sROBO1 antigen, in a dose-dependent manner. IC50
values for anti-ROBO1, DOTA-anti-ROBO1, and
90Y-anti-ROBO1 were 0.47, 0.41, and 0.51 μg/mL,
respectively. Similarly, IC50 values for anti-ROBO1,
DOTA-anti-ROBO1, and 111In-anti-ROBO1 were
0.41, 0.44, and 0.60 μg/mL, respectively. These
results indicate that the DOTA-anti-ROBO1 and
90Y- and 111In-anti-ROBO1 possess similar potency
as that of the anti-ROBO1.
3. Biodistribution of 111In-anti-ROBO1 MAb
The biodistribution study using 111In-anti-ROBO1
was carried out using HepG2 xenograft nude mice
(Figure 2). The tumour uptake of 111In-anti-ROBO1
was 4.68 ± 1.8, 9.22 ± 1.5, 15.0 ± 0.69, 11.5 ± 4.3,
12.6 ± 1.6, and 6.73 ± 1.1% ID/g at 6, 24, 48, 72,
144, and 240 h after injection, respectively. The
maximal tumour uptake of 111In-anti-ROBO1
occurred at 48 h after injection and then decreased
slowly.
High retention of tracer in the blood was observed
with 20.7% ± 1.9% ID/g at 6 h but decreased to
9.03 ± 2.1% ID/g at 72 h. 111In-anti-ROBO1 showed
high uptake in the liver with 12.6 ± 2.0% ID/g
at 48 h and then decreased to 9.9 ± 0.5% ID/g at
144 h.Figure 2 Biodistribution of 111In-anti-ROBO1 in HepG2 xenograft mice.
per gram of tissue (% ID/g).Kidney and spleen uptake of 111In-anti-ROBO1 was
8.24 ± 0.51% ID/g at 48 h and 7.87 ± 2.2% ID/g at
24 h, respectively.
In the sternum, the maximal uptake of 111In-anti-
ROBO1 was 1.80 ± 0.1% ID/g, and in the femoral
bone, it was 2.14 ± 0.005% ID/g at 24 h.
4. RIT and immunotherapy
The therapeutic efficacy of 90Y-anti-ROBO1 was
investigated in HepG2 xenograft mice (Figure 3).
The tumours in the 90Y-anti-ROBO1 group showed
significant growth inhibition, compared with growth
in the saline and cold-anti-ROBO1 groups from day
13 to 20 (p < 0.05); however, tumour regrowth was
observed at day 23. The cold-anti-ROBO1 did not
show any significant anti-tumour effect compared
with the saline treatment.
Animal body weight was measured after injection
(Figure 4a). Although the average body weight
decreased to about 90% of the original value in the
90Y-anti-ROBO1 group, the change was transient.
Other mice injected with saline or cold-anti-ROBO1
showed no significant reduction in body weight.
White blood cell (WBC), red blood cell (RBC), and
platelet (PLT) counts were measured after injection
(Figure 4b,c,d). The 90Y-anti-ROBO1 group showed
a reduction of WBC count to 40.3% ± 14.8% of the
original value. RBC and PLT counts of the 90Y-anti-
ROBO1 group were reduced to 68.4% ± 6.4% and
35.4% ± 6.4% of the original values, respectively.
Blood cell counts of the 90Y-anti-ROBO1 group
decreased significantly compared with those of the
saline and cold-anti-ROBO1 groups.
We performed H&E staining using paraffin sections
of resected tissues. Tumour cell degeneration,
determined by cell body swelling, chromatinResults represent the calculated percentages of the injected dose
Figure 3 Antitumour effect of 90Y-anti-ROBO1 in mouse
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day 7 and day 14 post injection (Figure 5b,c).
However, tumour cell degeneration decreased on
day 28. Pathological characteristics of tumour cells,
such as shape and size, were not altered andure 4 Effect of 90Y-anti-ROBO1 on body weight and blood counts in mo
,d) Blood cell count of HepG2 xenograft mice (diamonds, saline; squares, coldappeared to be the same as those observed at day 0
(Figure 5a,d).
The Ki-67 analysis showed a reduction of the prolif-
erative index in the 90Y-anti-ROBO1 group at day 14
(22.2% ± 6.8%) compared with that at day 0 (38.5% ±
4.5%, p < 0.05; Figure 6).
The percentage of TUNEL-positive cells on day 14
significantly increased (8.82% ± 1.8%) compared with
that at day 0 (3.28% ± 1.3%, p < 0.01; Figure 6).
No apparent pathological changes were observed in
the liver, kidney, or intestine (data not shown).
On day 7, the spleen showed a remarkable decrease
of hematopoietic cells in the red pulp (Figure 7a).
Regenerating hematopoietic foci of erythroid and
granulocytic cells were observed in 14 days. On day
28, regenerating megacaryocytes were observed.
Hematopoietic cells in the red pulp drastically
increased and comprised a large portion of the
spleen.
We performed Giemsa staining of the sternum and
femoral bone (Figure 7b,c). On day 7, a remarkable
decrease of hematopoietic cells was observed inuse models. (a) Mean body weight of HepG2 xenograft mice.
-anti-ROBO1; triangles, 90Y anti-ROBO1).
Figure 5 Histological analysis of tumours. (a) HepG2 tumour on day 0, original magnification × 400; (b) HepG2 tumour on day 7, original
magnification × 400; (c) HepG2 tumour on day 14, original magnification × 400; (d) HepG2 tumour on day 28, original magnification × 400.
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was reduced to about 20% to 50%, compared with
control count. The cell count recovered to
approximately 80% on day 28. In contrast, no
decrease of hematopoietic cells was observed in the
femoral bone marrow.ure 6 Quantitative analysis of cell proliferation and
ptosis. Ki-67: ratio of Ki-67-positive cells; TUNEL: ratio of
EL-positive cells. *p < 0.01Discussion
The results of this study are the first to demonstrate that
111In-anti-ROBO1 can target ROBO1 and that 90Y-anti-
ROBO1 has significant antitumour effects against HCC
xenografts.
To evaluate the ROBO1-binding affinity of the anti-
ROBO1, we performed cell ELISA. Anti-ROBO1 exhibited
high half-maximal binding (32.5 ng/mL) to cell surface
ROBO1 on ROBO1-expressing CHO cells. Then, we per-
formed competitive ELISA to evaluate the potency of
anti-ROBO1, DOTA-anti-ROBO1, and radioisotope
(RI)-labelled anti-ROBO1. The in vitro analysis confirmed
that DOTA conjugation and radiolabelling of anti-ROBO1
did not impair the receptor affinity for anti-ROBO1. There-
fore, it is reasonable to presume that anti-ROBO1 can be
used as an RI-labelled antibody.
We used 111In-anti-ROBO1 as a biodistribution surro-
gate to predict in vivo behaviours of 90Y-anti-ROBO1,
because previous reports indicate that 111In- and 90Y-la-
belled antibodies, proteins, and peptides are biologically
equivalent with respect to their uptake in tumours and
other major organs [17].
The results from the biodistribution studies show that
the uptake of 111In-anti-ROBO1 in HepG2 xenografts
was higher than that in unaffected organs. The tumour
uptake of radiotracer reached a maximum of 15.0% ±
Figure 7 Histological analysis of the spleen, sternum, and femoral bone. (a) Spleen, scale bar = 200 μm. (b) Sternum, scale bar = 100 μm. (c)
Femoral bone, scale bar = 100 μm.
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an extended period of time (12.6% ± 1.6% ID/g at 144 h
after injection). The uptake of radiotracer to unaffected
organs showed a maximum of 12.6% ± 2.1% in the liver
at 48 h, 8.24% ± 0.51% ID/g in the kidney at 48 h, and
7.87% ± 2.2% ID/g in the spleen at 24 h after injection,
but the uptake of each organ decreased gradually with
time. These results are similar to those reported in previ-
ous studies for RI-labelled IgGs specific for other antigens
[18-20]. Therefore, the results confirm that 111In-anti-
ROBO1 specifically targets ROBO1, and it is expected
that 90Y-anti-ROBO1 would accumulate in ROBO1-positive
tumours because of the similar binding specificity.
We injected 6.7 MBq of 90Y-anti-ROBO1 into HepG2
xenograft mice. 90Y-anti-ROBO1 significantly suppressed
tumour growth, compared with saline and cold-anti-
ROBO1 treatment. There was no significant difference
in tumour growth between the saline and cold-anti-
ROBO1 groups. These findings reveal that cold-anti-
ROBO1 has no significant antitumour effect.
90Y-anti-ROBO1 showed significant tumour growth
suppression, indicated by the measurement of tumour
volume, and we observed pathological changes, such as
cell degeneration and an increase in apoptotic cells. In
previous studies of RIT, the treated tumour showed
pathological changes, such as necrosis, apoptosis, fibrosis,and a decrease of Ki-67-positive cells [18-21]. Our patho-
logical analysis showed an increase of apoptotic cells and
a decrease of Ki-67-positive cells, without necrosis or
fibrosis. In contrast, cell degeneration, cell body swelling,
and chromatin compaction were observed. Cell degener-
ation is a common pathological change in treated tumour
tissues. Thus, our pathological analysis supports the
conclusion that 90Y-anti-ROBO1 possesses significant
antitumour effects when used in RIT.
Unfortunately, we observed tumour regrowth at about
day 20. In the pathological study, a decrease of cell de-
generation was observed at day 28; furthermore, the
shape and size of tumour cells appeared to be the same
as those observed at day 0. These results suggest that
the antitumour effect was insufficient to completely in-
hibit tumour growth. This phenomenon might be attrib-
uted to the radioresistance of solid tumours. Solid
tumours require a higher radiation dose for a complete
response compared with haematological malignancies,
which are radiosensitive [22]. Tumour cell hypoxia is
one of the main factors causing radioresistance [23]. In
this study, it is possible that hypoxic cells in the tumours
were induced, because the tumour volumes of the mice
were relatively large. Thus, tumour size might limit the
antitumour effects of RIT. Therefore, the injection of
90Y-anti-ROBO1 in combination with a radiosensitiser to
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tivity [24].
Body weight loss and an anaemic condition caused by
pancytopenia were observed. These conditions were
transient, and recovery was evident at the end of the ob-
servation period. No histopathological changes were ob-
served in the normal organs, but changes were observed
in the spleen and sternum bone marrow. Therefore, sys-
temic toxicity of 90Y-anti-ROBO1 was transient and lim-
ited to hematopoietic systems.
We observed a difference in the degree of damage
between the sternum and femur, although the biodis-
tribution study showed no significant difference of
111In-anti-ROBO1 accumulation between the two. These
contradictory results might be explained by the radiation
exposure from blood circulation and high accumulation
areas. Tumours in the right flank and liver showed high
accumulation of 111In-anti-ROBO1. In addition, the
cardiac pool was also a high accumulation area because of
the remaining of 111In-anti-ROBO1 in the blood. The
sternum is physically closer to these areas compared
to the femur; consequently, the different proximities are
the reason for the disparity observed in damage between
the two. Esteban et al. reported that radiation expos-
ure to the hematopoietic system can originate from
either circulating 90Y-MAb conjugate or non-specifically,
from nearby 90Y-MAb bound to a tumour [25,26]. Taken
together, the observations in this study and previous
reports suggest that the radiation exposure from a
high accumulation area is responsible for the damage
to hematopoietic tissues.
In this study, we evaluated the antitumour effects and
side effects of 90Y-anti-ROBO1 for an injection dose of
6.7 MBq. We determined the injection dose of 6.7 MBq,
based on an injection dose of 7.4 MBq that provided
maximal antitumour efficacy without animal mortality
[21]. The side effects, such as bone marrow suppression
and animal mortality, are the main limiting factors of
dose-escalation for enhancement of the therapeutic ef-
fect. In the toxicity study, we observed that the damage
to organs was transient and limited to the hematopoietic
systems. Hence, our data suggest that it might be pos-
sible to administer a higher dose of 90Y-anti-ROBO1. A
dose-escalation study is needed to determine a maximal
tolerated dose.
Conclusion
We evaluated a radiolabelled anti-ROBO1 IgG as a possible
candidate for RIT of HCC. Based on the biodistribution
study, administration of 111In-anti-ROBO1 demonstrated a
high accumulation to HepG2 xenografts, which represent
the human HCC model. Moreover, administration of 90Y-
anti-ROBO1 demonstrated antitumour activity towards
HepG2 xenografts, which was confirmed by a pathologicalstudy. In conclusion, our data suggest that administration
of 90Y-anti-ROBO1, which targets ROBO1, might become
an effective tool for RIT treatment of HCC and can
be applied to other ROBO1-positive cancers.
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